Efficacy of Flomax to Improve Stone Passage Following Shock Wave Lithotripsy

Stopped early · Not applicable · Has a placebo group

Conditions studied: Urolithiasis

In brief

The majority of kidney stones are treated with shock wave lithotripsy (SWL). We are examining if the medication Flomax will result in improved stone passage rates following SWL.

Key facts

Study ID

NCT00209131

Run by

Emory University

People needed

24

Starts

2005-04-01

Expected to finish

2009-02-01

Last updated by the study team

2013-10-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients 18 years old and above with urolithiasis scheduled for shock wave lithotripsy.

You may not qualify if…

• Contraindications to Flomax
• Patients with renal impairment (serum creatinine above 2.0)
• Patients with hepatic impairment (liver enzymes 2.5 times the upper limit of normal)
• Use of other oral alpha blockers

Where it is running

• Emory University — Atlanta, Georgia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.